TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of “Hold” by Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX) has earned an average rating of “Hold” from the nine research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $63.00.

A number of research firms have commented on TGTX. Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a research note on Wednesday, July 29th. JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. B. Riley Financial upped their price target on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a report on Monday, July 27th. HC Wainwright reiterated a “buy” rating and set a $78.00 price target on shares of TG Therapeutics in a research report on Tuesday, August 4th. Finally, Zacks Research raised shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st.

Institutional Trading of TG Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of TGTX. Danske Bank A S bought a new position in TG Therapeutics in the third quarter valued at about $25,000. EverSource Wealth Advisors LLC increased its position in TG Therapeutics by 51.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 365 shares in the last quarter. Hantz Financial Services Inc. increased its position in TG Therapeutics by 82.7% during the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 560 shares in the last quarter. Truvestments Capital LLC lifted its stake in TG Therapeutics by 172.4% in the 4th quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 1,026 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in TG Therapeutics in the 4th quarter valued at approximately $52,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $48.74 on Friday. The firm has a 50-day moving average price of $52.47 and a two-hundred day moving average price of $40.17. TG Therapeutics has a 12-month low of $26.76 and a 12-month high of $59.30. The company has a market capitalization of $7.46 billion, a P/E ratio of 17.79, a P/E/G ratio of 2.05 and a beta of 1.62. The company has a quick ratio of 3.72, a current ratio of 4.27 and a debt-to-equity ratio of 1.23.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.26). The business had revenue of $240.34 million for the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.The firm’s revenue for the quarter was up 70.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.17 earnings per share. Analysts anticipate that TG Therapeutics will post 0.92 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.